Serplulimab
Payments companies reported to CMS as associated with Serplulimab. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Serplulimab, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Serplulimab
These are the largest totals companies reported as associated with Serplulimab. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Deric Savior | Wynnewood, PA | Medical Oncology | $3,820.09 |
| David Gandara | Sacramento, CA | Hematology & Oncology | $3,820.09 |
| Anne Chiang | New Haven, CT | Medical Oncology | $3,820.09 |
| Jacob Sands | Burlington, MA | Hematology & Oncology | $3,220.09 |
| Vamsidhar Velcheti | Jacksonville, FL | Hematology & Oncology | $3,220.09 |
| Rafael Santana Davila | Seattle, WA | Hematology & Oncology | $3,220.09 |
| Jun Zhang | Iowa City, IA | Medical Oncology | $3,220.09 |
| Evan Wu | Fort Lauderdale, FL | Internal Medicine | $1,931.08 |
| Martin Edelman | Philadelphia, PA | Medical Oncology | $181.08 |
| Jianjun Zhang | Houston, TX | Internal Medicine | $181.08 |
Prescribed Serplulimab?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.